Anika Therapeutics, Inc.
ANIK
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $278.5M
$20.81
▼ -0.90%
P/E
-77.05
Mkt Cap
$278.5M
52-Wk Range
$8.37–$22.88
52-Week Range
$8.37 - $22.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 132.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary hyaluronic acid (HA) technology platform with 40+ years of development
- Diversified product portfolio across orthopedic and non-orthopedic applications
- Established market presence and regulatory approvals in US, Europe, and international markets
- Comprehensive joint preservation solutions addressing multiple patient needs and treatment stages
Bear Case
2 risks
- Low volatility (beta 0.2).
- Significant premium - growth priced in
Growth
Turning profitable
Rising osteoarthritis prevalence due to aging global population
Value
Significant premium - growth priced in
Momentum
Hot
+42.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying ANIK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of $0.42 vs $0.03 consensus (+1300.0% surprise). Revenue of $32.6M vs $29.2M expected (+11.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1300.0%
Revenue trend · last 8Q
—
-103%
-35%
-8%
-28%
—
+13%
+16%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$38.8M
-$1.3M
$26.2M
$28.2M
$27.8M
$30.6M
$29.6M
$32.6M
Margins · last 8Q
Gross
65.2%
Operating
9.1%
Profit
10.2%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Jul 30, 2026
vs Industry
How ANIK stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related